The present disclosure provides methods for the treatment of a subject having BRAF-mutated cancer cells comprising administering an effective amount of an eIF4E inhibitor, which may be optionally used in combination with other therapies, such as RAF inhibitors. Furthermore, BRAF mutational status can be used to select for patients that would clinically benefit from eIF4E inhibition, such as patient with BRAF-mutated cancer cells that are resistant to RAF kinase inhibitors.

The present disclosure provides methods for the treatment of a subject having BRAF-mutated cancer cells comprising administering an effective amount of an eIF4E inhibitor, which may be optionally used in combination with other therapies, such as RAF inhibitors. Furthermore, BRAF mutational status can be used to select for patients that would clinically benefit from eIF4E inhibition, such as patient with BRAF-mutated cancer cells that are resistant to RAF kinase inhibitors.

Provided herein are methods and compositions for dynamically controlling and targeting multiple immunosuppressive mechanisms in cancer. Some aspects provide cells engineered to produce multiple effector molecules, each of which modulates a different immunosuppressive mechanisms of a tumor, as well as methods of using the cells to treat cancer, such as ovarian, breast, or colon cancer.

Provided herein are methods and compositions for dynamically controlling and targeting multiple immunosuppressive mechanisms in cancer. Some aspects provide cells engineered to produce multiple effector molecules, each of which modulates a different immunosuppressive mechanisms of a tumor, as well as methods of using the cells to treat cancer, such as ovarian, breast, or colon cancer.

Proposed are a pharmaceutical composition for cancer treatment, comprising a prion protein-specific antibody, and a pharmaceutical composition for cancer treatment, comprising a complex of a target that binds to a prion protein antigenic determinant, and one or more selected from the group consisting of an anticancer drug, a chemotherapeutic agent, a toxin, a radioisotope, and a cytotoxic enzyme.

Proposed are a pharmaceutical composition for cancer treatment, comprising a prion protein-specific antibody, and a pharmaceutical composition for cancer treatment, comprising a complex of a target that binds to a prion protein antigenic determinant, and one or more selected from the group consisting of an anticancer drug, a chemotherapeutic agent, a toxin, a radioisotope, and a cytotoxic enzyme.

Provided herein are carrier cells and virus combinations and methods for treatment of cancers. Also provided are modified carrier cells for such treatment, and methods of selecting carrier cells that are matched to subjects for such treatment.

Provided herein are carrier cells and virus combinations and methods for treatment of cancers. Also provided are modified carrier cells for such treatment, and methods of selecting carrier cells that are matched to subjects for such treatment.

The present disclosure relates to nanoparticles containing cellular membrane and uses thereof. The nanoparticle comprises an interior compartment (or an inner core) and an outer surface (or shell) comprising a cellular membrane derived from a cell, said interior compartment (or an inner core) not providing a solid support to said cellular membrane in said outer surface (or shell). The present disclosure also relates to processes of making the nanoparticles. The present disclosure further relates to compositions comprising the nanoparticles and methods of using the nanoparticles.

Disclosed are potent immuno-DASH inhibitors and their use in the treatment of cell proliferative diseases.